Theranostic Potential of Early [18F]FDG-PET/CT in Guiding Erlotinib Therapy for Advanced Non-Small Cell Lung Cancer
The management of advanced non-small cell lung cancer (NSCLC) has evolved with the advent of targeted therapies such as erlotinib, which inhibit epidermal growth factor receptor (EGFR) signaling. However, identifying…